A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines - Takeaways - MDSpire

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

  • By

  • Yu-Hsiu Yen

  • Tzu-Wen Tsau

  • Chih-Hung Lee

  • Hsin-Han Chen

  • Chih-Hung Lin

  • Tim-Mo Chen

  • Chi-Ming Pu

  • November 1, 2025

  • 0 min

Share

  • 1

    The phase II trial evaluated the safety and efficacy of OBI-858, a novel botulinum toxin type A complex, for treating glabellar lines.

  • 2

    OBI-858 at a dose of 20U demonstrated significantly better wrinkle reduction compared to 10U and placebo, with effects lasting up to 24 weeks.

  • 3

    The study showed rapid onset of action and sustained patient satisfaction, indicating OBI-858's potential as a next-generation botulinum toxin.

  • 4

    Participants included adults aged 20 or older with moderate-to-severe glabellar lines, while those with certain medical conditions were excluded.

  • 5

    The trial was conducted in accordance with ethical guidelines and involved multiple centers in Taiwan, ensuring a robust study design.

Original Source(s)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

  • by Yu-Hsiu Yen, Tzu-Wen Tsau, Chih-Hung Lee, Hsin-Han Chen, Chih-Hung Lin, Tim-Mo Chen, Chi-Ming Pu

  • November 1, 2025

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Not All Vitamin C Serums Penetrate the Same

Skin penetration data reveals a wide gap between popular formulations